{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:40:33Z","timestamp":1779396033590,"version":"3.53.1"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p> HIV-infected people have started to live longer since the introduction of antiretroviral therapy, however various co-morbid illnesses have emerged. Three HIV-infected individuals, all at least 43\u2009years old, reported with a new onset of type 2 diabetes after switching to dolutegravir-combined antiretroviral therapy regimen. These three people were switched to integrase strand transfer inhibitor (dolutegravir)-based first-line antiretroviral treatment after receiving non-nucleoside reverse transcriptase inhibitor-combined first-line antiretroviral treatment for at least 6\u2009years, as recommended by the World Health Organization for Sub-Saharan African countries, including Ethiopia.All of the given cases had normal plasma fasting sugar (fasting blood sugar &lt;100\u2009mg\/dL) at the time of switching. Polyuria, polydipsia, considerable weight loss, and fatigue were all classified as signs of diabetes mellitus in the two male cases. In addition, their laboratory results demonstrated hyperglycemia (plasma fasting blood sugar &gt;\u2009200\u2009mg\/dL and urine glucose level \u2a7e2+) with no ketonuria after switching to dolutegravir for 4\u201310\u2009months. A glycemic control was achieved, and metformin medication was continued. After 6 months of dolutegravir treatment, the third female case developed diabetic ketoacidosis and severe hyperglycemia (fasting blood glucose level 600\u2009mg\/dL, urine glucose level 3+, and ketonuria 3+). To recover from diabetic ketoacidosis, the patient was given intravenous normal saline and regular insulin. Her glycemic control was then restored, and she was switched to NPH insulin. For all of the cases presented, the dolutegravir-based regimen was maintained. Antiretroviral regimens using dolutegravir have the potential to cause hyperglycemia and other side effects. As a result, blood glucose monitoring is required throughout treatment initiation and regularly throughout treatment follow-up, particularly for those on dolutegravir-combined antiretroviral therapy regimens. <\/jats:p>","DOI":"10.1177\/2050313x221079444","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T12:21:47Z","timestamp":1645618907000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4122-8151","authenticated-orcid":false,"given":"Agete Tadewos","family":"Hirigo","sequence":"first","affiliation":[{"name":"School of Medical Laboratory Sciences, College of Medicine and Health Science, Hawassa University, Hawassa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selamawit","family":"Gutema","sequence":"additional","affiliation":[{"name":"Hawassa Comprehensive Specialized Hospital, College of Medicine and Health Science, Hawassa University, Hawassa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aberash","family":"Eifa","sequence":"additional","affiliation":[{"name":"Department of Midwifery, College of Medicine and Health Science, Hawassa University, Hawassa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worku","family":"Ketema","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, College of Medicine and Health Science, Hawassa University, Hawassa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"bibr1-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.2174\/157016206775197664"},{"key":"bibr2-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"bibr3-2050313X221079444","unstructured":"Panel on Antiretroviral Guidelines for Adults Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services, http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf (accessed 4 August 2021)."},{"key":"bibr4-2050313X221079444","unstructured":"European AIDS Clinical Society. Guidelines. Clinical Management and Treatment of HIV Infected Adults in Europe. 7.1. November 2014, http:\/\/www.eacsociety.org\/Portals\/0\/GUIDELINES\/English%20PDF%20-%20Version%207.1.pdf (accessed 4 August 2021)."},{"key":"bibr5-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2000.04.986"},{"key":"bibr6-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030218"},{"key":"bibr7-2050313X221079444","volume-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"World Health Organization","year":"2018"},{"key":"bibr8-2050313X221079444","unstructured":"Ethiopia national consolidated guidelines for comprehensive HIV prevention, care and treatment, 2018, http:\/\/www.afro.who.int (accessed 4 August 2021)."},{"key":"bibr9-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2014.883169"},{"key":"bibr10-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.439"},{"key":"bibr11-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1016\/S0098-2997(02)00090-0"},{"key":"bibr12-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061351"},{"key":"bibr13-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209911"},{"key":"bibr14-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001495"},{"key":"bibr15-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1403"},{"key":"bibr16-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30042-4"},{"key":"bibr17-2050313X221079444","first-page":"69","volume":"20","author":"Hsu R","year":"2019","journal-title":"Inhiv Med"},{"key":"bibr18-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100615"},{"key":"bibr19-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx365"},{"key":"bibr20-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SUN-187"},{"key":"bibr21-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S323233"},{"key":"bibr22-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"bibr23-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1016\/S0098-2997(02)00090-0"},{"key":"bibr24-2050313X221079444","unstructured":"ViiV Healthcare. Tivicay (dolutegravir tablets). Full Prescribing Information. Viiv Healthcare, Research Triangle Park, NC 27709, 2018, https:\/\/www.gsksource.com\/pharma\/content\/.dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Tivicay\/pdf\/TIVICAY-PI-PIL.PDF (accessed 3 August 2021)."},{"key":"bibr25-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu051"},{"key":"bibr26-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61853-4"},{"key":"bibr27-2050313X221079444","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X221079444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X221079444","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X221079444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:57:25Z","timestamp":1740988645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X221079444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":27,"alternative-id":["10.1177\/2050313X221079444"],"URL":"https:\/\/doi.org\/10.1177\/2050313x221079444","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"2050313X221079444"}}